Some immunohistochemical markers of angiogenesis in melanocytic skin neoplasms.

Abstract

e21067 Background: The purpose of the study was to analyze the expression of angiogenesis-controlling markers (CD31, VEGF) in tissues of melanocytic skin lesions. Methods: The study included 20 patients with benign pigmented lesions and 15 patients with superficial spreading and nodular melanoma. Immunohistochemical study was performed on sections of paraffin blocks for standard morphological studies using murine monoclonal CD31 and VEGF antibodies. UltraVision Quanto Detection System HRP DAB was used for visualization. Angiogenesis in tumors was assessed by intratumoral microvessel density (iMVD) index. Microvessels were stained with anti-CD31 antibody. The number of vessels was determined in each area of sight using objective lens with 40x magnification and AxioVs40 v-4.8.1.0 program. The tumor was considered VEGF-positive if more than 25% of tumor cells showed positive staining, and percentages of these tumor cells were calculated in each case (in %). Results: Quantitative evaluation of iMVD showed that the median number of microvessels in an area of sight in melanoma and nevi was 10.0±0.9 and 4.1±0.4, respectively, results of CD31 expression were statistically significant (р˂0.05). The numbers of CD31-stained vessels in melanoma ranged from 4 to 18 in one area of sight. 14 nevus cases (70%) showed 4 and less vessels, and only giant-cell nevi (6-30%) demonstrated up to 15 vessels in one area of sight. VEGF expression was found in the cytoplasm of melanoma cells in 100% of cases (15), in nevi – in 65% (13). The expression was not found in nevi cells in 35% (7). The number of VEGF-positive cells varied greatly in both melanomas and in nevi – from less than 5% to 50%. The maximal VEGF expression was observed in melanomas – 32.5±2.9%, while in nevi 23.8±2.1% (р˂0.05). Conclusions: The immunohistochemical study demonstrated a high angiogenic potential of melanoma that can be used as an additional criterion for tumor progression and malignant transformation of melanocytic skin neoplasms and thus contribute to the development of novel approaches to the diagnosis of the disease.

Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin–Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor Microenvironment

“…Vascular endothelial growth factor (VEGF) and cluster of differentiation 31 (CD31) are markers of angiogenesis. − Western blotting for VEGF and CD31 showed that C4, C4 + IND, and HSA–IND–C4 decreased the expression of CD31 and VEGF in vitro (Figure A,B). A chick embryo chorioallantoic membrane (CAM) assay showed that the administration of C4, C4 + IND, and HSA–IND–C4 to the CAM led to a significant inhibition of neovascularization compared to that of the control (Figure C).…”

Autocrine/Paracrine Loop Between SCF+/c-Kit+ Mast Cells Promotes Cutaneous Melanoma Progression

“…Malignant melanoma progresses through different steps from common nevi, dysplastic nevi, in situ melanoma, radial growth phase melanoma, vertical growth phase melanoma, and metastatic melanoma ( 42 ). In parallel with tumor progression and dissemination, melanoma cells, in concert with microenvironment cells, orchestrate the angiogenic switch that favours tumor cell growth, extravasation and metastases ( 43 , 44 ).…”